The U.S. Court of Appeals for the Federal Circuit upheld a Virginia federal jury award to LifeNet Health of $34.7-million in damages for LifeCell’s infringement of a LifeNet patent related to improving the preservation of tissue grafts.
In November 2014, a jury found that LifeCell’s AlloDerm Ready to Use Regenerative Tissue Matrix and Strattice skin graft products infringed all seven asserted claims of LifeNet’s patent.
The LifeCell products are typically used in abdominal wall repair, breast reconstruction, and orthopedic surgical procedures. Novadaq (NASDAQ:NVDQ; TSX:NDQ) was appointed exclusive worldwide distributor of LifeNet’s DermACELL tissue products for wound and breast reconstruction surgery in December 2014.
“We’re happy to have the Federal Circuit affirm the jury’s verdict and recognize the value of LifeNet Health’s technology and look forward to development of future technologies that help further its goals of saving lives, restoring health and giving hope,” Douglas Wilson, EVP of LifeNet, said in a statement.